Autolus Therapeutics (NASDAQ:AUTL) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Autolus Therapeutics (NASDAQ:AUTL) issued its earnings results on Tuesday. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06, FiscalAI reports. The business had revenue of $45.69 million during the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative return on equity of 152.15% and a negative net margin of 238.66%.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• AUCATZYL net product revenue rose to $45.7 million in Q2 2026, up from $26.2 million in Q1 and $20.9 million a year earlier. Management raised full-year 2026 revenue guidance to $140 million–$150 million.
• Commercial expansion is progressing faster than planned, with more than 80 U.S. authorized treatment centers already active by midyear and approximately 20 U.K. centers expected by year-end. Management said most activated centers have already treated patients and reported strong physician adoption.
• Gross margin improved sharply to 55% from 6% in Q1, driven by higher manufacturing volumes, production at the U.K. Nucleus facility, operating efficiencies, and cost reductions. The company is targeting a 65%–70% gross margin for the mature adult ALL business within roughly 12–18 months.
• Management outlined multiple upcoming clinical catalysts, including longer-term CARLYSLE lupus data and initial AUTO8 amyloidosis data by year-end 2026, BOBCAT progressive multiple sclerosis data in 2027, and potential pediatric ALL and lupus nephritis milestones in 2027–2028.
• Autolus drew an initial $75 million under a Perceptive Advisors credit facility, with up to $250 million potentially available subject to revenue milestones. Combined with cash, marketable securities, and anticipated revenue, management expects runway into Q2 2028, though the financing increases future debt obligations.

Autolus Therapeutics Trading Down 9.0%

AUTL stock opened at $2.12 on Thursday. The firm has a market cap of $564.26 million, a PE ratio of -2.00 and a beta of 2.07. Autolus Therapeutics has a 1 year low of $1.17 and a 1 year high of $2.43. The company has a fifty day simple moving average of $1.62 and a 200 day simple moving average of $1.56.

Analyst Ratings Changes

A number of brokerages have commented on AUTL. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Wall Street Zen upgraded Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Finally, Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Marex Group plc bought a new stake in shares of Autolus Therapeutics during the 2nd quarter worth about $28,000. SmartHarvest Portfolios LLC bought a new position in shares of Autolus Therapeutics in the 4th quarter valued at approximately $43,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Autolus Therapeutics in the 3rd quarter valued at approximately $46,000. Invesco Ltd. raised its stake in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after acquiring an additional 11,381 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec acquired a new position in Autolus Therapeutics during the fourth quarter valued at approximately $62,000. 72.83% of the stock is currently owned by institutional investors.

Trending Headlines about Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Autolus reported second-quarter EPS of $(0.15), better than the $(0.21) analyst consensus, while revenue of $45.69 million exceeded expectations of $38.56 million. The results helped drive an initial increase in the shares. Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
• Positive Sentiment: Management’s higher AUCATZYL guidance and reported launch momentum strengthened the outlook for commercial growth, supporting investor optimism about the company’s cell-therapy business. Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $10 price target. The firm improved its FY2026 EPS forecast to $(0.81) from $(0.88), and also slightly raised its FY2029 and FY2030 estimates to $(0.68) and $(0.21), respectively.
• Neutral Sentiment: The company’s earnings remain deeply negative, with a reported net margin of negative 238.66% and return on equity of negative 152.15%. Investors are therefore likely to focus on AUCATZYL sales growth, cash usage and the path toward profitability rather than the quarterly beat alone.
• Negative Sentiment: HC Wainwright modestly reduced its Q4 2026 EPS forecast to $(0.20) from $(0.19), indicating that near-term losses may be slightly worse than previously expected. The stock’s decline after its initial post-earnings increase may reflect profit-taking and lingering concerns about sustained losses.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.